Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 7/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29643377 | 0.84 | TSHR (0.51) | TSHRCYP3A4ALDH1A1 | |
| SCHEMBL19063495 | 0.84 | TSHR (0.51) | TSHRCYP3A4ALDH1A1 | |
| SCHEMBL28479818 | 0.81 | CYP2C9 (0.45) | CYP3A4MAPTGRM5CYP1A2CYP2D6 | |
| SCHEMBL4462628 | 0.77 | GRM5 (0.47) | CYP3A4GRM5CYP1A2CYP2D6CYP2A6 | |
| SCHEMBL12984706 | 0.75 | TSHR (0.46) | TSHRCYP3A4MAPTALDH1A1GRM5 | |
| SCHEMBL15218940 | 0.74 | TSHR (0.53) | TSHRCYP3A4MAPTALDH1A1 | |
| SCHEMBL4468465 | 0.73 | MEN1 (0.49) | TSHRCYP3A4MAPTALDH1A1CYP2A6 | |
| SCHEMBL31673182 | 0.73 | GRM5 (0.71) | CYP3A4GRM5CYP1A2CYP2D6CYP2A6 | |
| SCHEMBL1476990 | 0.73 | GRM5 (0.71) | CYP3A4GRM5CYP1A2CYP2D6CYP2A6 | |
| SCHEMBL3837529 | 0.72 | GRM5 (0.62) | CYP3A4GRM5CYP1A2CYP2D6CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560462-B2 | Compounds useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080214573-A1 | Compounds Useful for Inhibiting Chk1 | ICOS CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| CN-101010316-A | Compounds useful for inhibiting CHK1 | ICOS CORP (US) | 2007-08-01 | — | — | CN | disclosed |
| EP-1768977-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006014359-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214573-A1 | Compounds Useful for Inhibiting Chk1 | ORC3, MCM3, CHEK1 | TSHR 1478/4885CYP3A4 3598/4885MAPT 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.